A BRCA1-Like, 25-Gene Assay Predicts for Anthracycline-Chemosensitivity in Sporadic Triple-Negative Breast Cancer.

被引：0
|
作者：
Rodriguez, A. A. [1 ]
Rimawi, M. [1 ]
Wu, M-F [1 ]
Dave, B. [1 ]
Wong, H. [1 ]
Landis, M. [1 ]
Cairo, M. [1 ]
Pavlick, A. [1 ]
Froehlich, A. [1 ]
Chamness, G. [1 ]
Hilsenbeck, S. G. [1 ]
Lewis, M. T. [1 ]
Osborne, C. K. [1 ]
Chang, J. [1 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509S / 509S
页数：1
相关论文
共 50 条
  • [21] Circulatory insulin-like growth factor 1 predicts metastasis in triple-negative breast cancer
    Akter, Salima
    Faruque, Mithila
    Akhter, Hajara
    Bhowmik, Mousumi
    Hasan, Mohammad Nazmul
    Sultana, Lipika
    Khan, Imran
    Mia, Mamun
    Rahman, Md Mustafizur
    Chaudhury, Habib Sadat
    Rafiqul, Islam S.
    Nahar, Kamrun
    Choi, Tae Gyu
    Kim, Sung Soo
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [22] Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer
    Su, L.
    Zhang, J.
    Meng, H.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    [J]. CLINICAL GENETICS, 2018, 94 (01) : 165 - 169
  • [23] A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
    Zheng, Tianzhi
    Pang, Zhiyuan
    Zhao, Zhao
    [J]. BIOSCIENCE REPORTS, 2019, 39
  • [24] Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC)
    Sharma, Priyanka
    Stecklein, Shane R.
    Kimler, Bruce F.
    Khan, Qamar J.
    Connor, Carol Sue
    McGinness, Marilee
    Mammen, Joshua
    Wagner, Jamie Lynn
    Jensen, Roy A.
    Godwin, Andrew K.
    Fabian, Carol J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
    Y. L. Xu
    R. Yao
    J. Li
    Y. D. Zhou
    F. Mao
    B. Pan
    Q. Sun
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 1205 - 1213
  • [26] A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
    Mitri, Zahi Ibrahim
    Vuky, Jacqueline
    Kemmer, Kathleen A.
    Savin, Michael A.
    Parmar, Swapnil
    Kolodzie, Annette Kolodzie
    Johnson, Brett
    Williams-Belizaire, Rochelle
    Gray, Joe W.
    Mills, Gordon B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
    Xu, Y. L.
    Yao, R.
    Li, J.
    Zhou, Y. D.
    Mao, F.
    Pan, B.
    Sun, Q.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1205 - 1213
  • [28] BRCA1 methylation contributes to the triple-negative breast cancer phenotype.
    Nwachukwu, C.
    Grushko, T. A.
    Xu, J.
    Khramtsov, A.
    Olopade, O., I
    [J]. CANCER RESEARCH, 2009, 69 (02) : 266S - 266S
  • [29] Transcriptoma analyses in triple-negative breast cancer with BRCA1 germline mutation
    Nakamura, Kivvi Duarte
    Ferreira, Elisa
    Ramalho, Rodrigo
    Brianese, Rafael
    Carraro, Dirce
    [J]. CANCER RESEARCH, 2017, 77
  • [30] Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
    Maksimenko, Jelena
    Irmejs, Arvids
    Nakazawa-Miklasevica, Miki
    Melbarde-Gorkusa, Inga
    Trofimovics, Genadijs
    Gardovskis, Janis
    Miklasevics, Edvins
    [J]. ONCOLOGY LETTERS, 2014, 7 (01) : 278 - 284
12345